Effective Spesolimab Treatment for Generalized Pustular Psoriasis Masquerading as Acute Generalized Exanthematous Pustulosis: A Case Report
Kazuyoshi Iijima, Yuko Akiyama, Itsumi Mizukawa, Megumi Hirabayashi, Yoshihiro Kuwano
TL;DR
This case report describes a successful treatment of generalized pustular psoriasis with spesolimab, a drug targeting the IL-36 receptor.
Contribution
The report highlights spesolimab's efficacy in a complex GPP case with AGEP-like features, emphasizing accurate diagnosis.
Findings
Spesolimab rapidly relieved symptoms in a GPP patient with AGEP-like features.
Accurate diagnosis is crucial for effective treatment of GPP.
Real-world evidence supports spesolimab's role in managing severe GPP flares.
Abstract
Generalized pustular psoriasis (GPP) is a rare and severe variant of psoriasis, often posing diagnostic challenges due to its clinical overlap with acute generalized exanthematous pustulosis (AGEP), a severe drug-induced hypersensitivity reaction. Spesolimab, a monoclonal antibody targeting the interleukin 36 (IL-36) receptor, provides rapid symptom relief for GPP flares, but real-world data remain limited. We report a case of GPP complicated by overlapping features with AGEP, highlighting the importance of precise diagnosis and the efficacy of spesolimab.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDrug-Induced Adverse Reactions · Psoriasis: Treatment and Pathogenesis · Autoimmune Bullous Skin Diseases